Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: FAM133B (ImmuneEditome ID:257415)

1. Gene summary of enriched editing regions for FAM133B

Gene summary

Gene information	Gene symbol	FAM133B
	Gene ID	257415
	GeneSynonyms	-
	GeneCytomap	7q21.2
	GeneType	protein-coding
	GeneDescription	protein FAM133B
	GeneModificationdate	20230329
	UniprotID	Q5BKY9;G3XAI9;H0YH72;C9JUX2
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr7:92566941-92568238:-	ENST00000468931.1	ENSG00000234545.6	FAM133B	ncRNA_intronic	MER20B,(AATAC)n,AluSx,AluJr	chr7:92566941-92568238:-.alignment
chr7:92566941-92568238:-	ENST00000481407.4	ENSG00000234545.6	FAM133B	ncRNA_intronic	MER20B,(AATAC)n,AluSx,AluJr	chr7:92566941-92568238:-.alignment
chr7:92573216-92573479:-	ENST00000468931.1	ENSG00000234545.6	FAM133B	ncRNA_intronic	(T)n,AluJr4	chr7:92573216-92573479:-.alignment
chr7:92573216-92573479:-	ENST00000481407.4	ENSG00000234545.6	FAM133B	ncRNA_intronic	(T)n,AluJr4	chr7:92573216-92573479:-.alignment
chr7:92573216-92573479:-	ENST00000490747.1	ENSG00000234545.6	FAM133B	ncRNA_intronic	(T)n,AluJr4	chr7:92573216-92573479:-.alignment

Top

2. Tumor-specific enriched editing regions for FAM133B

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

StageType

AnovaP

Boxplot

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for FAM133B

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for FAM133B

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000234545.6,FAM133B

ESCA

EAG

ENSG00000115274.10

chr2

74455022:74455174:74455405:74455598

-0.4442

2.2991e-03

2.0416e-06

-0.4228

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

ENSG00000234545.6,FAM133B

ESCA

EAG

ENSG00000182670.9

chr21

37158130:37158203:37159698:37159745

-0.3247

3.2399e-02

3.1424e-05

-0.4239

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZC3H7B;ZFP36;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HYPOXIA

ENSG00000234545.6,FAM133B

ESCA

EAG

ENSG00000168003.12

chr11

62883988:62884112:62884456:62884512

-0.4079

1.4867e-02

1.1673e-06

-0.4370

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

SLC3A2

T_cells_CD4_memory_resting

GSVA_HALLMARK_P53_PATHWAY

ENSG00000234545.6,FAM133B

ESCA

EAG

ENSG00000129484.9

chr14

20357050:20357520:20357637:20357776

-0.3883

2.3563e-02

4.6601e-06

-0.4091

ACIN1;ADAR;AIFM1;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184

B_cells_naive

GSVA_HALLMARK_MTORC1_SIGNALING

ENSG00000234545.6,FAM133B

ESCA

EAG

ENSG00000119431.5

chr9

113375452:113375567:113376728:113376925

-0.3860

3.7168e-02

3.7676e-06

-0.4143

AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LIN28;LSM11;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;XRN2;YTHDC1;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_GLYCOLYSIS

ENSG00000234545.6,FAM133B

ESCA

EAG

ENSG00000090621.9

chr1

39563613:39563741:39563832:39563922

-0.3505

3.1009e-02

4.9168e-06

-0.4098

ACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZC3H7B;ZFP36;ZNF184

PABPC4

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MTORC1_SIGNALING

More results

Top

5. Enriched editing regions and immune infiltration for FAM133B

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr7:92566941-92568238:-	ESCA	EER	T_cells_regulatory_(Tregs)	2.8034e-04	-0.3782
ENSG00000234545.6,FAM133B	ESCA	EAG	T_cells_CD4_memory_activated	3.9994e-03	0.2642
ENSG00000234545.6,FAM133B	LAML	EAG	T_cells_gamma_delta	3.8176e-02	0.3376
chr7:92573216-92573479:-	OV	EER	Dendritic_cells_resting	4.6061e-02	0.2990
ENSG00000234545.6,FAM133B	OV	EAG	Neutrophils	1.6861e-02	0.2911
chr7:92566941-92568238:-	STAD	EER	Plasma_cells	1.0298e-02	0.2374
ENSG00000234545.6,FAM133B	STAD	EAG	T_cells_regulatory_(Tregs)	7.1220e-03	-0.1810

Top

6. Enriched editing regions and immune gene sets for FAM133B

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000234545.6,FAM133B	STAD	EAG	1.1152e-02	0.1708	2.0475e-02	0.1562	2.6708e-02	0.1494	3.1843e-04	0.2405
chr7:92566941-92568238:-	STAD	EER	2.9491e-02	0.2022	4.3719e-02	0.1876	2.1420e-02	0.2134	1.9147e-02	0.2173

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000234545.6,FAM133B	ESCA	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	1.1554e-04	0.3489
chr7:92566941-92568238:-	ESCA	GSVA_HALLMARK_P53_PATHWAY	EER	2.0299e-02	0.2471
ENSG00000234545.6,FAM133B	LAML	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	3.9490e-02	-0.3355
ENSG00000234545.6,FAM133B	OV	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.2290e-02	0.3043
chr7:92573216-92573479:-	OV	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	3.8731e-03	0.4221
chr7:92566941-92568238:-	STAD	GSVA_HALLMARK_UV_RESPONSE_UP	EER	6.2237e-05	0.3630
ENSG00000234545.6,FAM133B	STAD	GSVA_HALLMARK_GLYCOLYSIS	EAG	1.2509e-05	0.2898

Top

7. Enriched editing regions and drugs for FAM133B

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000234545.6,FAM133B	ESCA	CGP.60474	EAG	7.3761e-04	-0.3077
chr7:92566941-92568238:-	ESCA	CGP.082996	EER	3.7428e-05	-0.4246
ENSG00000234545.6,FAM133B	LAML	AUY922	EAG	4.6666e-03	-0.4492
chr7:92573216-92573479:-	OV	BI.2536	EER	5.8152e-03	0.4048
chr7:92566941-92568238:-	STAD	CCT007093	EER	1.1494e-03	0.2982
ENSG00000234545.6,FAM133B	STAD	JW.7.52.1	EAG	1.8643e-02	-0.1585

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType